Comparison of the effects of L-type calcium channel antagonist Amlodipine with L/N-type calcium channel antagonist Cilnidipine on blood pressure, heart rate, proteinuria and lipid profile in hypertensive patients

Singal KK1, Singal N2, Gupta A3, Garg A4, Kumar R5

Abstract:

Background: Cilnidipine is a novel and unique 1,4-dihydropyridine derivative calcium antagonist that exerts potent inhibitory actions not only on L-type but also on N-type voltage dependent calcium channels. Blockade of the neural N-type calcium channel inhibits the secretion of norepinephrine from peripheral neural terminals and depresses sympathetic nervous system activity. Objective and methods: The purpose of this study was to assess the effect of Cilnidipine and Amlodipine on blood pressure (BP) levels. We did BP monitoring before and after once-daily use of Cilnidipine and Amlodipine in 100 hypertensive patients. Results: Both drugs significantly reduced systolic BP (SBP) and diastolic BP (DBP). However, the reductions in pulse rate (PR) were significantly greater in the Cilnidipine group than the Amlodipine group. N-type calcium channel blockade by Cilnidipine may not cause reflex tachycardia, and may be useful for hypertensive treatment. Conclusion: There was significant reduction in proteinuria with Cilnidipine as compared to Amlodipine. However, there were no significant change in total cholesterol level in diabetes and non-diabetics in both the group.

Keywords: calcium channel antagonist; cilnidipine; amlodipine; hypertension; proteinuria; pulse rate (PR); systolic BP (SBP); diastolic BP (DBP)
of mortality in congestive heart failure patients. De Champlain showed a sustained rise in blood norepinephrine levels by more than 50% after chronic therapy of Amlodipine. The inhibitory effect on the N-type Ca²⁺ channel by Cilnidipine may bestow an additional clinical advantage for the treatment of hypertension, such as suppression of reflex tachycardia. In morning, arousal from sleep is associated with rise in plasma epinephrine. Cilnidipine due to its sympathetic inhibitory action was more effective than Amlodipine therapy in controlling morning BP in hypertensive patients. In spontaneously hypertensive rats (SHR) treated with N-w-nitro-L-arginine-methylester (L-NAME), Cilnidipine dilates afferent and efferent arterioles in the kidney and decrease glomerular capillary pressure, thereby decreasing proteinuria and improving glomerulosclerosis. In addition a comparative study of Cilnidipine and an ACEI benazepril, has shown that both regimens similarly reduced urine albumin. Cilnidipine a dual L-and N-type calcium channel blocker may be useful for patients with hypertension and diabetes mellitus from its effects on lipid metabolism and renal function. Previous reports indicates beneficial effect of Cilnidipine on lipid profile in addition to the antihypertensive activity.

**Methods:**

**Study design:** We undertook randomized, open label comparative study of two groups of hypertensive patients between June 2013 to December 2013. Total 100 patients were recruited for this study. One group comprising of 50 patients were taking 5-10mg Amlodipine and other group comprising of 50 patients were taking 10-20 mg Cilnidipine. In Amlodipine group, 20 patients and in Cilnidipine group, 25 patients were diabetic. The numbers of proteinuric patients were 12 and 14 in Amlodipine and Cilnidipine group respectively.

**Study procedure:** After taken written informed consent patients were screened for selection criteria. Cilnidipine was administered orally at the dose of 10mg. In 10 patients the magnitude of reduction was insufficient (a difference in SBP<20mmHg or decrease in DBP<10mmHg). In these patients dose was increased to 20 mg once daily. Amlodipine was administered orally once daily at the dose of 5mg. In 20 patients dose was increased to 10mg once daily when BP was not successfully controlled. BP and Pulse rate were monitored. In proteinuric patient’s urinary protein content were standardized for urinary excretion of 1g creatinine. Values represent the mean of two measurements of each time points during the observation period. Serum concentration of total cholesterol, HDL-C, LDL-C and TG were determined by the enzymatic methods with an autoanalyzer. All DM patients in this study were diagnosed as type 2. Dyslipidemia was defined on the basis of abnormal lipid level LDL-Cholesterol (LDL-C) ≥140mg/dl, HDL-Cholesterol(HDL-C) <40mg/dl,Triglyceride (TG) ≥150mg/dl).

**Statistical Analysis:** Values were expressed as the mean±SD. The difference of the baseline characteristics and change in BP and PR parameter between the Amlodipine and Cilnidipine groups was compared using an unpaired t-test. The difference between the values before and after antihypertensive medication within the same group was tested using a paired t-test. P-value <0.05 considered statistically significant.

Research design and protocol of this study was approved by Ethics Committee of MMIMSR.

**Results:**

Table 1 summarizes the baseline characteristics of the patients enrolled for this study. There were no statistically significant differences between the two groups at baseline in terms of age, sex, and baseline SBP, DBP, and PR. Seren concentration of total cholesterol, HDL-C, LDL-C and TG were determined by the enzymatic methods with an autoanalyzer.

**Table 1:** The baseline characteristics of the patients

<table>
<thead>
<tr>
<th></th>
<th>Amlodipine (n=50)</th>
<th>Cilnidipine (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (%)</td>
<td>70</td>
<td>58</td>
</tr>
<tr>
<td>Age (years)</td>
<td>60 (±4)</td>
<td>64 (±5)</td>
</tr>
<tr>
<td>No. with diabetes</td>
<td>22</td>
<td>18</td>
</tr>
<tr>
<td>No. with proteinuria</td>
<td>15</td>
<td>12</td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td>24±3</td>
<td>24±2</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>160±11</td>
<td>160±12</td>
</tr>
<tr>
<td>DBP(mmHg)</td>
<td>94±9.8</td>
<td>90±9</td>
</tr>
<tr>
<td>PR (bpm)</td>
<td>78±9</td>
<td>76±6.4</td>
</tr>
</tbody>
</table>

Figure 1: shows the effect of Amlodipine and Cilnidipine on the PR levels. In the Amlodipine group, PR after treatment was significantly higher than that before treatment.
Table 2: Blood Pressure Before and After Treatment

<table>
<thead>
<tr>
<th></th>
<th>Amlodipine Before</th>
<th>Amlodipine After</th>
<th>Cilnidipine Before</th>
<th>Cilnidipine After</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP (mmHg)</td>
<td>160±11</td>
<td>146±10</td>
<td>160±12</td>
<td>148±11</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>94±9.8</td>
<td>86±7.4</td>
<td>90±9</td>
<td>82±10</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Figure 2: shows the effect of Amlodipine and Cilnidipine on excretion of protein after treatment. The protein/creatinine ratio was significantly lower with Cilnidipine than Amlodipine group.

Discussion:
Epidemiological studies have demonstrated that a higher heart rate is associated with a long term risk of cardiovascular mortality, independent of other cardiac risk factors. It has been reported that treatment with short acting calcium antagonist may not prevent cardiovascular disease. Accordingly, long lasting calcium channel blockers that exert less influence on the sympathetic nervous system are now recommended for treatment of hypertension. A recent clinical trial demonstrated that lowering of BP was associated with a significant fall in cardiovascular event. In this study once daily use of Amlodipine or Cilnidipine significantly reduced the BP. We found that Cilnidipine but not Amlodipine significantly decreased the BP level without causing an increase in PR. There have been previous reports that compared the effects of Amlodipine and Cilnidipine. There was a significant negative correlation between the degree of SBP change and that of PR change after Cilnidipine treatment. This finding is an agreement with several previous studies in which Cilnidipine suppressed sympathetic nervous activity, especially under a stress-induced hyperactive condition.
Blood pressure control is important in suppressing the onset of renal dysfunction. It was reported that antihypertensive therapy suppressed the progression of renal dysfunction. Regarding glomerular kinetics, it has been shown that inhibition of angiotensin II suppress the elevation of glomerular pressure. Among CCBs, Cilnidipine has been reported...
Comparison of the effects of L-type calcium channel antagonist

Furthermore, regarding the effect of Cilnidipine and Amlodipine on renal function, Kojima et al, reported that the level of urinary protein elevated after Amlodipine treatment in urinary protein positive hypertensive patients as compared to baseline level, while there was no significant difference in the level of urinary protein before and after Cilnidipine treatment. Fujita et al conducted a CARTER study involving patients with hypertension and chronic renal disease demonstrating that urinary protein during renin-angiotensin inhibitor therapy was further reduced by concomitant use of Cilnidipine but it was not further reduced by concomitant Amlodipine use. The result from the present study were identical to those of previous reports. A possible mechanism for the renal protection effects of Cilnidipine, unlikely the other CCBs has been explained as follows. Since L type calcium channels are present primarily on afferent arterioles, the inhibition of these channels causes dilatation of only afferent arterioles, resulting in elevation of glomerular pressure. On the other hand, N-type calcium channels, which are located in sympathetic nerve endings, control both afferent and efferent arterioles, thus resulting in well-balanced dilatation of both arterioles.

Concerning lipid metabolism, neither total cholesterol, HDL-C nor LDL-C level with Amlodipine differed significantly from those with Cilnidipine in DM(+) groups. With Amlodipine, TG was significantly higher in DM (+) group than in DM(-) group, while no such difference was noted with Cilnidipine. These results indicate that Cilnidipine reduces TG in hypertensive patients with diabetes mellitus. The results from this study were identical to those of previous reports.

Acknowledgement: The authors thank the patients for their consent to participate in the study and wish to acknowledge for every the support from M. M. Institute of Medical Sciences & Resarch, Mullana (Ambala), India for supporting to conduct the study.

Conflict of interest: None declared.
References:


16. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with


